Fate Therapeutics (FATE) Total Liabilities (2012 - 2026)
Fate Therapeutics (FATE) posted Total Liabilities of $284.9 million for Q1 2026, down 10.67% on a QoQ basis from $318.9 million in Q4 2025, and down 28.53% year-over-year from $398.7 million in Q1 2025.
Fate Therapeutics (FATE) Total Liabilities (2012 - 2026) Analysis & Trends
Fate Therapeutics' Total Liabilities history runs 15 years deep, the most recent figure standing at $284.9 million for Q1 2026.
- Quarterly Total Liabilities fell 28.53% year-over-year to $284.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $284.9 million (down 28.53% YoY) and the FY2025 annual result came in at $318.9 million, down 27.63% from the prior year.
- Total Liabilities was $284.9 million for Q1 2026 at Fate Therapeutics, down from $318.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $858.4 million in Q1 2022 and bottomed at $284.9 million in Q1 2026.
- A 5-year average of $537.5 million and a median of $528.8 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities retreated 8.98% — and 2025, when it slumped 30.57%.
- Fate Therapeutics' Total Liabilities stood at $705.6 million in 2022, then retreated by 28.25% to $506.2 million in 2023, then retreated by 12.94% to $440.7 million in 2024, then dropped by 27.63% to $318.9 million in 2025, then retreated by 10.67% to $284.9 million in 2026.
- Business Quant data shows FATE's Total Liabilities at $284.9 million in Q1 2026, $318.9 million in Q4 2025, and $343.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 177.22 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 3.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 7.33 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.62 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 753.82 Mn |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | 284.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 284.92 Mn |
| Dec 31, 2025 | 318.94 Mn |
| Sep 30, 2025 | 343.67 Mn |
| Jun 30, 2025 | 371.63 Mn |
| Mar 31, 2025 | 398.67 Mn |
| Dec 31, 2024 | 440.69 Mn |
| Sep 30, 2024 | 494.97 Mn |
| Jun 30, 2024 | 528.82 Mn |
| Mar 31, 2024 | 569.89 Mn |
| Dec 31, 2023 | 506.22 Mn |
| Sep 30, 2023 | 543.79 Mn |
| Jun 30, 2023 | 584.76 Mn |
| Mar 31, 2023 | 630.34 Mn |
| Dec 31, 2022 | 705.56 Mn |
| Sep 30, 2022 | 749.35 Mn |
| Jun 30, 2022 | 807.06 Mn |
| Mar 31, 2022 | 858.39 Mn |
| Dec 31, 2021 | 921.46 Mn |
| Sep 30, 2021 | 984.57 Mn |
| Jun 30, 2021 | 1.02 Bn |